Quote:

---

My takeaway from the PR is this, and it is no small matter:

Quote:

---

The Company confirmed that 5/5 patients (100%) who demonstrated a significant increase in PD-L1 expression after receiving leronlimab and received treatment with any ICI remain alive today. Four of these patients (80%) currently identify as having no evidence of disease, and the fifth patient is alive and identified by the clinical site as “stable.”

---

EVERY patient who had a significant increase in PD-L1 expression after receiving Leron is alive today.

---

66.6% aren't. What we need to know is how many of those 66.6% were also using PD-1 inhibitors. If it was only those 5 or there were only a couple of the 66.6% that were then it would trend towards a leronlimab/ PD-1 inhibitor combo being a winner. It may be something as simple as every one of the 17 being on 525mg or 700mg and those 5 having less disease severity or genetics that respond better to leronlimab. That's why I like to have data it's the only way to parse out what's going on.